Novo Ventures, the ventures arm of Novo Holdings, is pleased to note the $146.6 million Initial Public Offering on NASDAQ of its portfolio company VectivBio Holdings AG [VECT]. VectivBio is a Swiss company focused on the development of Apraglutide, a next-generation, long-acting, synthetic GLP-2 analog for short bowel syndrome, currently in Phase 3 clinical development.

For further information, please find the full statement here.